OncoMatch/Clinical Trials/NCT07028125
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Is NCT07028125 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies cabozantinib and nivolumab for renal cell carcinoma (kidney cancer).
Treatment: cabozantinib and nivolumab — The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07028125 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages